EMA Application withdrawn: Comfyde (carisbamate) — Janssen-Cilag International NV

View source ↗

Summary

EMA withdrew the application for Comfyde (carisbamate) by Janssen-Cilag International NV in epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Comfyde (carisbamate)

Snippet

Status: Application withdrawn. Therapeutic area: Epilepsy. MAH: Janssen-Cilag International NV. Decision date: 31/12/2009